The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. | The company is working ...
MedPage Today on MSN
Gene Therapy Supply Runs Out, Company Warns of Treatment Delays
Hemgenix for hemophilia B is temporarily unavailable, says maker CSL Behring ...
KING OF PRUSSIA, Pa., Aug. 3, 2021 /PRNewswire/ -- CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug.
CSL Behring has made a name for itself manufacturing biologics and plasma, but its unveiling of a new R&D site—slated to be the company’s largest—is evidence of expanded development efforts. The new ...
The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...
HEMGENIX ® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years ...
- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Hemgenix will have a list price ...
KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results